Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Audisio, R. A.
Right arrow Articles by Tiberio, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Audisio, R. A.
Right arrow Articles by Tiberio, G.

Annals of Surgical Oncology, Vol 3, Issue 4 349-357, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Follow-up in colorectal cancer patients: a cost-benefit analysis

R. A. Audisio, P. Setti-Carraro, M. Segala, D. Capko, B. Andreoni and G. Tiberio
Istituto di Chirurgia d'Urgenza, Universita di Milano, Italy.

BACKGROUND: No conclusive evidence exists concerning the effectiveness of follow-up programs after curative surgery for colorectal cancer, and presently cost-benefit analyses have not indicated that follow-up strategies increase survival or quality of life. METHODS: Five hundred five patients who survived curative surgery for stage I-III colorectal adenocarcinoma were closely followed for at least 4 years. RESULTS: One hundred forty-one (28%) patients had recurrence. Of these, 32 underwent one or more surgical procedures for cure, whereas 109 could only benefit from palliation. Eighteen were cured. The mean survival of all recurrent cases was 44.4 months. Of those operated on with curative intent, the mean survival was 69.3 months compared with 37.1 months in those operated on with palliative intent. Of those 18 patients who were cured by reoperative surgery, the average survival was 81.4 months. The overall follow-up cost was $1,914,900 (U.S.) for the 505 patients; $13,580 (U.S.) for each recurrence, $59,841 (U.S.) for each case treated for cure, and $136,779 (U.S.) for those effectively cured. CONCLUSIONS: Careful postoperative monitoring is expensive yet effective when one considers that one-quarter of the detected recurrences were suitable for potentially curative second surgery; however, only 3.6% of the original group were effectively cured. Follow-up programs should be tailored according to the stage and site of the primary to reduce costs.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
H. Korner, K. Soreide, P. J. Stokkeland, and J. A. Soreide
Diagnostic Accuracy of Serum-Carcinoembryonic Antigen in Recurrent Colorectal Cancer: A Receiver Operating Characteristic Curve Analysis
Ann. Surg. Oncol., February 1, 2007; 14(2): 417 - 423.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Garbe, A. Paul, H. Kohler-Spath, U. Ellwanger, W. Stroebel, M. Schwarz, B. Schlagenhauff, F. Meier, B. Schittek, H.-J. Blaheta, et al.
Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy
J. Clin. Oncol., February 1, 2003; 21(3): 520 - 529.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.